Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

Rhea-AI Summary

Aquestive Therapeutics (NASDAQ: AQST) has scheduled its fourth quarter 2024 financial results announcement for March 5, 2025, after market close. The pharmaceutical company will host a conference call for investors on March 6, 2025, at 8:00 a.m. ET to discuss the results and provide updates on recent business developments.

Investors can participate in the conference call by registering in advance to obtain their local or toll-free phone number and personal pin. A live webcast will be available on the Investors section of Aquestive's website, with a 30-day archive period following the call.

WARREN, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2024 and provide an update on recent developments in its business after market close on Wednesday, March 5, 2025.

Management will host a conference call for investors at 8:00 a.m. ET on Thursday, March 6, 2025. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.

A live webcast of the call will be available on the Investors section of Aquestive’s website at: Fourth Quarter 2024 Earnings Call.

Following the call, a replay of the webcast will be available on the Investors section of the Company’s website at https://investors.aquestive.com/events-and-presentations. The webcast will be archived for 30 days.

About Aquestive Therapeutics
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products marketed by the Company and its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an earlier stage epinephrine prodrug topical gel product candidate for the treatment of possible various dermatology conditions, including alopecia areata. For more information, visit Aquestive.com and follow us on LinkedIn.

Forward-Looking Statement
Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement for clinical development and approval by the U.S. Food and Drug Administration of the Company’s product candidates, including AQST-109 for the treatment of severe allergic reactions, including anaphylaxis, and AQST-108 for the treatment of possible various dermatology conditions, including alopecia areata. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.

PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.

Investor Inquiries
Astr partners
Brian Korb
Brian.korb@astrpartners.com

FAQ

When will Aquestive Therapeutics (AQST) release Q4 2024 earnings?

Aquestive Therapeutics will release its Q4 2024 earnings after market close on Wednesday, March 5, 2025.

What time is AQST's Q4 2024 earnings conference call?

The earnings conference call is scheduled for Thursday, March 6, 2025, at 8:00 a.m. ET.

How can investors access AQST's Q4 2024 earnings call?

Investors need to register in advance to obtain a phone number and personal pin. A live webcast will also be available on Aquestive's Investors website section.

How long will AQST's Q4 2024 earnings call webcast be available?

The webcast will be archived on the company's Investors section for 30 days following the call.